Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 8:50 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Gonadorelin Clear all
Active, not recruiting Phase 3 Interventional

Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial

NCT05050084
View directory record Official record
Conditions
Prostate Adenocarcinoma
Interventions
Bicalutamide, Buserelin, Darolutamide, Degarelix, Flutamide, Goserelin, Histrelin, Leuprolide, Radiation Therapy, Relugolix, Triptorelin
Drug · Radiation
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
2,050 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
567
States / cities
Birmingham, Alabama • Gilbert, Arizona • Peoria, Arizona + 432 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 23, 2026, 8:50 PM EDT
Withdrawn Phase 2 Interventional

Randomized Phase II Study of ADT + Abiraterone vs ADT + Docetaxel + Abiraterone

NCT06060587
View directory record Official record
Conditions
Prostate Cancer
Interventions
Docetaxel, ADT, Abiraterone
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Sep 23, 2026, 8:50 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

The Use of GnRH Agonist Trigger in the Prevention of OHSS

NCT00349258
View directory record Official record
Conditions
Ovarian Hyperstimulation Syndrome
Interventions
Leuprolide acetate
Drug
Lead sponsor
University of Connecticut
Other
Eligibility
20 Years to 39 Years · Female only
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 5, 2006 · Synced Sep 23, 2026, 8:50 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Comparison Elagolix vs Depot Leuprolide Prior to Frozen Embryo Transfers in Patients With Endometriosis

NCT04445025
View directory record Official record
Conditions
Infertility, Endometriosis
Interventions
Elagolix 200 MG, Leuprolide Acetate 3.75 MG/ML, Lab work
Drug · Diagnostic Test
Lead sponsor
Colorado Center for Reproductive Medicine
Other
Eligibility
21 Years to 42 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Lone Tree, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 19, 2025 · Synced Sep 23, 2026, 8:50 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Endometrial Receptivity Profile in Patients With Endometrial Proliferation Defects

NCT02406690
View directory record Official record
Conditions
Endometrial Dysfunction
Interventions
Estradiol Valerate, Progesterone in Oil, Leuprolide
Other
Lead sponsor
Reproductive Medicine Associates of New Jersey
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Basking Ridge, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 1, 2017 · Synced Sep 23, 2026, 8:50 PM EDT
Completed Phase 2 Interventional Results available

EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer

NCT01360840
View directory record Official record
Conditions
Prostate Cancer Metastatic
Interventions
EMD 525797, Placebo, Standard of Care (SoC)
Drug · Other
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years and older · Male only
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
12
States / cities
Pleasant Hill, California • Chicago, Illinois • New Orleans, Louisiana + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2015 · Synced Sep 23, 2026, 8:50 PM EDT
Completed Phase 2 Interventional Results available

Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) With Leuprolide + Letrozole and (3) Everolimus + EDT in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLL-HCC)

NCT01642186
View directory record Official record
Conditions
Fibrolamellar Carcinoma, Fibrolamellar Liver Cancer
Interventions
everolimus, letrozole plus leuprolide, combination of everolimus, letrozole and leuprolide
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
12 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
6
States / cities
San Francisco, California • Baltimore, Maryland • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2022 · Synced Sep 23, 2026, 8:50 PM EDT
Completed Phase 2 Interventional Results available

AASUR in High Risk Prostate Cancer

NCT02772588
View directory record Official record
Conditions
Prostate Cancer
Interventions
ARN-509, Abiraterone, Leuprolide, stereotactic, ultra-fractionated radiotherapy
Drug · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
11
States / cities
Baltimore, Maryland • Ann Arbor, Michigan • Middletown, New Jersey + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 23, 2026, 8:50 PM EDT
Completed Phase 2 Interventional Results available

Exisulind and Intermittent Androgen Suppression (ADT) in Biochemical Relapsed Prostate Cancer

NCT00283803
View directory record Official record
Conditions
Prostate Cancer
Interventions
Exisulind, luteinizing hormone-releasing hormone (LHRH) agonist, Antiandrogen
Drug
Lead sponsor
University of Washington
Other
Eligibility
21 Years and older · Male only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 6, 2018 · Synced Sep 23, 2026, 8:50 PM EDT
Recruiting Phase 2 Interventional

Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT

NCT07455903
View directory record Official record
Conditions
Prostate Cancer, Localized Prostate Carcinoma
Interventions
Leuprolide, Degarelix, Relugolix, Triptorelin, Bicalutamide, 18-F Flotufolastat PSMA PET, Radical prostatectomy
Drug · Diagnostic Test · Procedure
Lead sponsor
Baptist Health South Florida
Other
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 23, 2026, 8:50 PM EDT
Completed Phase 2 Interventional Results available

Rapid Hormonal Cycling as Treatment for Patients With Prostate Cancer: The Men's Cycle

NCT00586898
View directory record Official record
Conditions
Prostate, Cancer, Hormonal Cycling
Interventions
GnRH, Ketoconazole, Bicalutamide, Testosterone transdermal gel, Estrogen transdermal patch
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 24, 2016 · Synced Sep 23, 2026, 8:50 PM EDT
Not listed Phase 2 Interventional

Study to Evaluate the Pharmacodynamics and Efficacy of Leuprolide Tablets (Ovarest®) in Women With Endometriosis

NCT05096065
View directory record Official record
Conditions
Endometriosis
Interventions
Leuprolide Oral Tablet - 120 mg - QD- Treatment A, Leuprolide Oral Tablet - 80 mg - QD - Treatment B, Leuprolide Oral Tablet - 60 mg - QD - Treatment C, Leuprolide Oral Tablet - 60 mg - BID - Treatment D, Leuprolide Oral Tablet - 40 mg - BID - Treatment E
Drug
Lead sponsor
Enteris BioPharma Inc.
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
4
States / cities
Sarasota, Florida • Columbus, Ohio • Norfolk, Virginia + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2022 · Synced Sep 23, 2026, 8:50 PM EDT
Active, not recruiting Phase 3 Interventional

A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy

NCT03767244
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Apalutamide, Androgen Deprivation Therapy (ADT), Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
2,517 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
44
States / cities
La Jolla, California • Los Angeles, California • Orange, California + 36 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 23, 2026, 8:50 PM EDT
Completed Phase 1 Interventional

Cytoreductive Prostatectomy in Treating Patients With Newly Diagnosed, Metastatic Prostate Cancer

NCT02458716
View directory record Official record
Conditions
Metastatic Prostate Carcinoma, Metastatic Prostatic Adenocarcinoma, Prostate Carcinoma Metastatic to the Bone
Interventions
Robotic Assisted Radical Prostatectomy, Conventional open retropubic radical prostectomy, Laboratory Biomarker Analysis, Quality-of-Life Assessment, ADT (androgen deprivation therapy) (i.e. leuprolide) plus an androgen receptor inhibitor (i.e. bicalutamide)
Procedure · Other · Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older · Male only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
3
States / cities
Duarte, California • Orange, California • New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 7, 2021 · Synced Sep 23, 2026, 8:50 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Menopause Effects on Vascular Function

NCT03236545
View directory record Official record
Conditions
Cardiovascular Risk Factor
Interventions
No to Low Endogenous Estrogen, Estradiol
Other
Lead sponsor
University of Delaware
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Nov 13, 2022 · Synced Sep 23, 2026, 8:50 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate the Ability of Lupron Depot to Enhance Immune Function Following Bone Marrow Transplantation

NCT00275262
View directory record Official record
Conditions
Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Mantle Cell Lymphoma
Interventions
Leuprolide acetate depot (LAD) 11.25 mg 3 Month, Matched placebo
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
4
States / cities
St Louis, Missouri • New York, New York • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated May 5, 2010 · Synced Sep 23, 2026, 8:50 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate Cancer

NCT04194554
View directory record Official record
Conditions
Prostate Cancer
Interventions
Niraparib, Leuprolide, Abiraterone Acetate, Stereotactic body radiotherapy (SBRT)
Drug · Radiation
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
6
States / cities
Ann Arbor, Michigan • Rochester, Minnesota • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Sep 23, 2026, 8:50 PM EDT
Recruiting Phase 3 Interventional

REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial

NCT06650579
View directory record Official record
Conditions
Recurrent Prostate Carcinoma, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
Interventions
Abiraterone Acetate, Bicalutamide, Biospecimen Collection, Computed Tomography Angiography, Leuprolide, Prednisone, Radiation Therapy, Relugolix
Drug · Procedure · Radiation
Lead sponsor
Emory University
Other
Eligibility
18 Years and older · Male only
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
4
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Sep 23, 2026, 8:50 PM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC

NCT02941926
View directory record Official record
Conditions
Breast Cancer
Interventions
Ribociclib, Letrozole, Goserelin, Leuprolide
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
3,246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
71
States / cities
Anchorage, Alaska • Chandler, Arizona • Phoenix, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2023 · Synced Sep 23, 2026, 8:50 PM EDT
Completed Not applicable Interventional

Studies in Porphyria IV: Gonadotropin-Releasing Hormone (GnRH) Analogues for Prevention of Cyclic Attacks

NCT00004330
View directory record Official record
Conditions
Porphyria
Interventions
luteinizing hormone-releasing factor
Drug
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
18 Years to 55 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1987
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 23, 2026, 8:50 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Skeletal Health and Bone Marrow Composition Among Youth

NCT04203381
View directory record Official record
Conditions
Gender Dysphoria in Children, Puberty, Bone Development
Interventions
GnRH Agonist
Device
Lead sponsor
Amy DiVasta, MD
Other
Eligibility
9 Years to 14 Years
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
2
States / cities
Boston, Massachusetts • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Sep 23, 2026, 8:50 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effects of Dietary Omega-3 Fatty Acids on Reproductive Hormones in Obese Women

NCT01894581
View directory record Official record
Conditions
Obesity, Fertility
Interventions
LOVAZA, GnRH
Dietary Supplement · Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 42 Years · Female only
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 1, 2017 · Synced Sep 23, 2026, 8:50 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Investigating the Regulation of Reproductive Hormones in Adult Men

NCT00392457
View directory record Official record
Conditions
Kallmann Syndrome, Hypogonadism, Gonadal Disorder
Interventions
ketoconazole, gonadotropin releasing hormone (GnRH)
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 50 Years · Male only
Enrollment
175 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1995 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 15, 2015 · Synced Sep 23, 2026, 8:50 PM EDT
Completed No phase listed Observational

Intramuscular Mechanisms of Androgen Deprivation-related Sarcopenia

NCT03867357
View directory record Official record
Conditions
Metastatic Prostate Cancer, Androgen Deprivation Therapy
Interventions
GnRH agonist
Drug
Lead sponsor
Seattle Institute for Biomedical and Clinical Research
Other
Eligibility
18 Years to 90 Years · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 3, 2024 · Synced Sep 23, 2026, 8:50 PM EDT